News | September 08, 2010

Ticagrelor Demonstrates Advantages Over Clopidogrel

September 8, 2010 – The increased effectiveness of ticagrelor (Brilinta) in overcoming high platelet reactivity as compared to the gold-standard of clopidogrel (Plavix) was shown in data presented last week at the European Society of Cardiology (ESC) Congress in Stockholm.

Pooled pharmacologic data from the ONSET/OFFSET and RESPOND trials compared high platelet reactivity between clopidogrel and ticagrelor use. This reactivity has been linked to complications following percutaneous coronary intervention (PCI).

Ticagrelor showed better platelet inhibition and faster offset than clopidogrel in the ONSET/OFFSET study. The RESPOND study also confirmed better platelet inhibition with ticagrelor in both clopidogrel responders and nonresponders. The effects of ticagrelor were observed within two hours, while clopidogrel took between four and eight hours.

One of the chief advantages of ticagrelor is its ability to reverse its effects quickly as compared to clopidogrel, which was also demonstrated in these data.

In July, the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted to recommend that the FDA approve ticagrelor for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). The panel reviewed data from the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study, an outcomes trial of more than 18,000 patients whose data showed ticagrelor was superior to clopidogrel in the long-term reduction of cardiovascular events.

The FDA is expected to make an approval decision this month.

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init